Suven Pharmaceuticals Limited (NSE: SUVENPHAR)

Market Cap	305.52B
Revenue (ttm)	9.34B
Net Income (ttm)	2.40B
Shares Out	254.56M
EPS (ttm)	9.45
PE Ratio	127.04
Forward PE	82.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,404,987
Open	1,140.00
Previous Close	1,151.10
Day's Range	1,140.00 - 1,224.00
52-Week Range	507.00 - 1,224.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Suven Pharmaceuticals

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 1,193
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SUVENPHAR

Financial Performance

In 2023, SUVENPHAR's revenue was 10.51 billion, a decrease of -21.56% compared to the previous year's 13.40 billion. Earnings were 3.00 billion, a decrease of -26.99%.